Daiichi Sankyo & AstraZeneca's Datroway approved in China to treat unresectable or metastatic TNBC who are not candidates for PD─1/PD─L1 inhibitor therapy
Datroway (datopotamab deruxtecan) has been approved in China for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD─1/PD─L1 inhibitor
Full article text belongs to the original publisher. Moogle News shows the headline/summary and sends you to the source.
Read full story on publisher site →